Get the Stockscreener App
4.28
2.64%
0.11
After Hours:
4.22
-0.06
-1.40%
X 4 Pharmaceuticals Inc stock is traded at $4.28, with a volume of 684.87K.
It is up +2.64% in the last 24 hours and up +35.44% over the past month.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
See More
Previous Close:
$4.17
Open:
$4.14
24h Volume:
684.87K
Relative Volume:
1.18
Market Cap:
$389.14M
Revenue:
$33.98M
Net Income/Loss:
$-95.10M
P/E Ratio:
-0.4277
EPS:
-10.0072
Net Cash Flow:
$-106.13M
1W Performance:
+15.99%
1M Performance:
+35.44%
6M Performance:
+35.02%
1Y Performance:
-53.13%
1-Day Range:
$4.10
$4.50
1-Week Range:
$3.53
$4.50
52-Week Range:
$1.35
$9.564
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Name
X 4 Pharmaceuticals Inc
Sector
Industry
Phone
857-529-8300
Address
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR vs VRTX, REGN, ALNY, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
4.28 | 389.14M | 33.98M | -95.10M | -106.13M | -10.01 |
VRTX
Vertex Pharmaceuticals Inc
|
454.00 | 115.33B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
732.87 | 77.48B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.17 | 41.40B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
663.93 | 41.09B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
275.28 | 30.56B | 5.36B | 287.73M | 924.18M | 2.5229 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-09-26 | Initiated | Guggenheim | Buy |
| Dec-05-25 | Resumed | Stifel | Buy |
| Dec-12-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Aug-30-23 | Resumed | B. Riley Securities | Buy |
| Dec-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | ROTH Capital | Buy |
| Dec-09-19 | Upgrade | Citigroup | Neutral → Buy |
| Dec-05-19 | Initiated | B. Riley FBR | Buy |
| Jun-07-19 | Initiated | Stifel | Buy |
| Jun-05-19 | Initiated | Cowen | Outperform |
View All
X 4 Pharmaceuticals Inc Stock (XFOR) Latest News
PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide) - PR Newswire
X4 Pharmaceuticals (NASDAQ: XFOR) seeks approval for equity plan and pay at 2026 meeting - Stock Titan
Tarsus (NASDAQ: TARS) HR chief sells 12,274 shares in tax-related trades - Stock Titan
Tax-driven stock sale by Tarsus (TARS) chief commercial officer - Stock Titan
Children’s ibuprofen sold nationwide recalled by FDA - FOX8 WGHP
Analysts’ Top Healthcare Picks: X4 Pharmaceuticals (XFOR), Boston Scientific (BSX) - The Globe and Mail
Research Analysts Set Expectations for XFOR Q1 Earnings - MarketBeat
Crinetics Pharmaceuticals (CRNX) COO sells 9,911 shares for RSU taxes - Stock Titan
RA Capital entities boost Acumen (NASDAQ: ABOS) stake with 6.1M-share grant - Stock Titan
X4 Pharmaceuticals (NASDAQ:XFOR) Issues Quarterly Earnings Results - MarketBeat
[Form 4] Amphastar Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
X4 Pharmaceuticals, Inc. 2025 Annual Report: Business Overview, Regulatory Compliance, and Risk Factors - Minichart
X4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
XFOR: 4WARD Phase 3 trial progresses, EMA backs mavorixafor, and cash runway extends to 2028 - TradingView
X4 Pharmaceuticals: Q4 Earnings Snapshot - 10TV
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Yahoo Finance
X4 Pharmaceuticals 2025 10-K: $35.1M Revenue, $(79.2)M Net Loss - TradingView
XFOR: 2025 revenue surged to $35.1M, but net loss increased to $79.2M amid restructuring and R&D focus - TradingView
X4 Pharmaceuticals (NASDAQ: XFOR) cuts costs, raises cash to advance mavorixafor - Stock Titan
X4 Pharmaceuticals (XFOR) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Amneal Pharmaceuticals: Flattish 2026 Revenue Growth Aside, Stock Still Looks A Buy (AMRX) - Seeking Alpha
Zacks Industry Outlook Highlights Terns Pharmaceuticals, ADMA Biologics, ANI Pharmaceuticals and Liquidia - TradingView
Ionis Pharmaceuticals, Inc. $IONS Shares Purchased by Jain Global LLC - MarketBeat
X4 Pharmaceuticals, Inc. $XFOR Shares Acquired by Kingdon Capital Management L.L.C. - MarketBeat
Apellis Pharmaceuticals, Inc. $APLS Shares Bought by HighVista Strategies LLC - MarketBeat
Aug Sectors: Is X4 Pharmaceuticals Inc impacted by rising ratesPortfolio Risk Summary & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
X4 Pharmaceuticals Inc (XFOR) Stock News & Articles - 24/7 Wall St.
Apellis (NASDAQ: APLS) CEO gifts 129,738 shares via family trusts - Stock Titan
Cigna Stock Trades Below Industry P/E: Is It Worth Holding Now? - TradingView
Rosalind Advisors Inc. Makes New Investment in X4 Pharmaceuticals, Inc. $XFOR - MarketBeat
Xenon Pharmaceuticals (NASDAQ: XENE) CLO sale covers RSU taxes - Stock Titan
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Layoff Tracker: Vistagen, Evotec, Reckitt Benckiser Downsize, Collectively Affecting Hundreds - BioSpace
Equity awards and tax withholding for Amphastar Pharmaceuticals (AMPH) insiders - Stock Titan
Recursion (NASDAQ: RXRX) director converts 20K Class B, gifts 20K A - Stock Titan
X4 Pharmaceuticals at Leerink Global Healthcare Conference: Strategic Shift to Rare Hematology - Investing.com
Amphastar (AMPH) CEO logs 10,850-share RSU tax withholding, retains large stake - Stock Titan
Geopolitical Volatility Boosts Value Investing: 4 Low-PEG Picks - TradingView
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Aug Summary: Is X4 Pharmaceuticals Inc impacted by rising ratesTrade Analysis Report & Stepwise Swing Trade Plans - baoquankhu1.vn
Amylyx (NASDAQ: AMLX) CFO receives new stock options and RSU grant - Stock Titan
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention - Yahoo Finance
Guggenheim initiates X4 Pharmaceuticals stock with buy rating - Investing.com Australia
Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS) - Yahoo Finance
Xenon Pharmaceuticals to Announce Topline Data from Phase 3 X-TOLE2 Study of Azetukalner for Focal Onset Seizures - Quiver Quantitative
Phase 3 seizure drug data Monday in Xenon focal onset study - Stock Titan
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance Singapore
Can X4 Pharmaceuticals Inc lead its sector in growthJuly 2025 Reactions & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
According to the latest filing disclosed by the U.S. Securities and Exchange Commission (SEC), InMed Pharmaceuticals Inc (INM) officially confirmed and passed a resolution on March 4 to gradually terminate the commercial operations of its Baymedica divisio - Bitget
Renal Cancer Clinical Trial Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com
Tarsus (TARS) COO executes 8,366-share Rule 10b5-1 plan sale - Stock Titan
X 4 Pharmaceuticals Inc Stock (XFOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
X 4 Pharmaceuticals Inc Stock (XFOR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Baldry Mark | Chief Commercial Officer |
May 16 '25 |
Buy |
2.48 |
1,032 |
2,561 |
25,337 |
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):